Company intelligence / Profile preview

Intrommune Therapeutics

New York, New York, United Statesintrommune.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Intrommune Therapeutics has developed a novel oral mucosal immunotherapy platform that embeds allergenic proteins into toothpaste. Their lead product, INT301, targets peanut allergy and has completed a Phase I trial demonstrating safety. A multi-center North American Phase II trial in children with peanut allergies was planned to start late 2022 or early 2023. The OMIT approach aims to desensitize patients by daily exposure during toothbrushing, offering a convenient alternative to current therapies.

Therapeutic areas: Immunology
Modalities: Oral mucosal immunotherapy (OMIT)allergen-specific immunotherapy via toothpaste platform
Industry: Biotech

Drug pipeline

2 assets

INT301

1 more asset in the full pipeline.

Request access →

Partnerships

Inimmune Corporation – collaboration announced January 2024 to combine Intrommune’s OMIT technology with Inimmune’s rapid desensitization therapy for enhanced treatment of peanut allergies.

Beyond the preview

Go deeper on Intrommune Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intrommune Therapeutics.

Explore the full profile